26.9 C
Karachi
Friday, April 19, 2024
- Advertisement -

Erdogan announces local development of anti-Covid drug

TOP NEWS

Web Desk
Web Desk
News Stories Posted by ARY News Digital Team

A Japanese-developed flu drug, favipiravir, (also known as Avigan) has been shown to be effective in both reducing the duration of the novel coronavirus in patients and improving the condition of their lungs, its main point of attack.

Turkey will locally develop and produce favipiravir, in COVID-19 treatment, President Recep Tayyip Erdoğan said today after Turkish scientists were able to synthesize the drug’s active ingredient.

The drug will be available for coronavirus treatment after the registration process is completed, Erdoğan said after Turkey held its first face-to-face cabinet meeting in three months.

According to the Ministry of Health, favipiravir brought from China is being used under a ‘unique’ protocol in Turkey.

Read More: US has 2 million doses of coronavirus vaccine, claims Trump

Unlike Chinese doctors, Turkish doctors have discovered that early incubation extends the length of the disease while giving high-flow oxygen leads to more successful and faster treatment.

Erdoğan also announced a further easing of several restrictions imposed to curb the spread of COVID-19.

Marriage registration halls will reopen on June 15, followed by wedding halls on July 1. Meanwhile, businesses such as cinemas, theaters and exhibition centers will be allowed to reopen from July 1, under government-specified regulations.

Citizens above the age of 65 will be allowed outside between 10 a.m. and 8 p.m. every day, while those under 18 will be able to go out anytime with their parents. People above 65 and minors were previously banned from leaving their homes, apart from certain days of the week.

Turkey launched its normalization process at the beginning of this month, gradually lifting a number of social restrictions.

- Advertisement -
- Advertisement -
 

POLL

Will the PML-N led govt be able to steer Pakistan out of economic crisis?

- Advertisement -
 

MORE STORIES